SAN MATEO, Calif.--(BUSINESS WIRE)--EpiBiologics, a leader in tissue-selective extracellular protein degradation, will be presenting new data demonstrating the unique capabilities of its EpiTAC platform at the 16th Annual PEGS Europe conference (November 5-7, 2024 in Barcelona, Spain) and the 2024 Antibody Engineering and Therapeutics US conference (December 15-18, 2024 in San Diego, California)..

加利福尼亚州圣马特奥（商业新闻短讯）--组织选择性细胞外蛋白降解领域的领导者EpiBiologics将在第16届PEGS欧洲年会（2024年11月5日至7日，西班牙巴塞罗那）和2024年抗体工程与治疗美国会议（2024年12月15日至18日，加利福尼亚州圣地亚哥）上展示其EpiTAC平台的独特功能。。

“We’re pleased to present in vivo data demonstrating significant platform validation and the potential for meaningful therapeutic benefit of EpiTACs not only in oncology, where our initial focus has been, but also in high-need immune disorders,” said Shyra Gardai, Ph.D., Chief Scientific Officer of EpiBiologics..

EpiBiologics首席科学官Shyra Gardai博士说：“我们很高兴提供体内数据，证明了显着的平台验证以及EpiTACs不仅在肿瘤学领域（我们最初的重点是肿瘤学）而且在高需求免疫疾病领域具有有意义的治疗益处的潜力。”。。

EpiTAC bispecific antibodies leverage cell-surface degrader receptors enriched in disease tissue to selectively degrade membrane and extracellular targets with activity superior to antibody or small molecule blockade. New data being presented demonstrate EpiTACs’ ability to remove target proteins specifically in disease tissue, sparing healthy tissue and increasing efficacy..

EpiTAC双特异性抗体利用富含疾病组织的细胞表面降解受体选择性降解膜和细胞外靶标，其活性优于抗体或小分子阻断剂。正在提供的新数据表明，EpiTACs能够特异性去除疾病组织中的靶蛋白，保留健康组织并提高疗效。。

Presentation Highlights

By selecting degrader receptors enriched in disease tissue, EpiBiologics reports that its EGFR-targeting bispecific EpiTAC antibody drives synergistic anti-tumor activity in vivo while preserving EGFR signaling in normal tissue.

通过选择富含疾病组织的降解受体，EpiBiologics报道其靶向EGFR的双特异性EpiTAC抗体在体内驱动协同抗肿瘤活性，同时在正常组织中保留EGFR信号传导。

EGFR EpiTAC also achieves mutation-agnostic degradation of EGFR in multiple tumor models, enabling a meaningful therapeutic approach for broad patient populations in non-small cell lung cancer (NSCLC) and other EGFR-driven cancers.

EGFR EpiTAC还可以在多种肿瘤模型中实现EGFR的突变不可知降解，从而为非小细胞肺癌（NSCLC）和其他EGFR驱动的癌症的广泛患者群体提供了一种有意义的治疗方法。

EpiTACs exhibit potential in autoimmunity by localizing degradation to T regulatory cells and driving cell-selective activity. This provides a powerful approach to overcoming limitations of immune therapies that simultaneously affect both pro- and anti-inflammatory immune cells, limiting their effectiveness..

EPITAC通过将降解定位于T调节细胞并驱动细胞选择性活性而显示出自身免疫的潜力。这为克服同时影响促炎和抗炎免疫细胞的免疫疗法的局限性提供了一种强有力的方法，从而限制了它们的有效性。。

The EpiTAC platform can degrade disease-causing GPCRs by a number of different strategies. Targeted degradation of GPCRs is a key achievement given their importance in a number of diseases, including pain and autoimmune/inflammatory and neurological diseases.

EpiTAC平台可以通过多种不同的策略降解引起疾病的GPCR。鉴于GPCR在许多疾病中的重要性，包括疼痛和自身免疫/炎症和神经系统疾病，GPCR的靶向降解是一项关键成就。

“EpiBiologics has achieved major milestones this year, including advancing a tissue-selective EGFR program toward the clinic, localizing degradation to specific immune cell subsets for autoimmunity, and degrading GPCRs, a difficult-to-drug target class,” said Ann Lee-Karlon, Ph.D., President and CEO of EpiBiologics.

EpiBiologics总裁兼首席执行官AnnLeeKarlon博士说：“EpiBiologics今年取得了重大里程碑，包括将组织选择性EGFR计划推向临床，将降解定位于自身免疫的特定免疫细胞亚群，以及降解难以药物靶向的GPCR。”。

“We are excited to expand the breadth of our platform to address a wide range of diseases while making important progress on our pipeline of EpiTAC bispecific antibody therapies.”.

“我们很高兴扩大平台的广度，以解决广泛的疾病，同时在我们的EpiTAC双特异性抗体治疗管道上取得重要进展。”。

Details of the oral presentations are as follows:

口头陈述的细节如下：

16th Annual PEGS Europe

欧洲第16届年度PEGS

Title: “EpiTACs Are a Novel Bispecific Antibody Platform to Degrade Disease-Driving Extracellular Targets”

标题：“EpiTAC是一种新型双特异性抗体平台，可降解疾病驱动的细胞外靶标”

Date & Time: Wednesday, November 6th, 11:15 a.m. CET

日期和时间：欧洲中部时间11月6日星期三上午11:15

Presenter: Shyra Gardai, Ph.D.

主持人：Shyra Gardai博士。

2024 Antibody Engineering & Therapeutics US

2024抗体工程与治疗美国

Title: “EpiTACs Are a Novel Bispecific Antibody Platform that Drive the Degradation of Disease-Driving Targets”

标题：“EpiTAC是一种新型双特异性抗体平台，可驱动疾病驱动靶标的降解”

Date & Time: Monday, December 16th, 4:45 p.m. PT

日期和时间：12月16日星期一下午4:45 PT

Presenter: Shyra Gardai, Ph.D.

主持人：Shyra Gardai博士。

About EpiBiologics

关于EpiBiologics

EpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets membrane and extracellular proteins. EpiBiologics was founded on pioneering work from scientific founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular bispecific antibody system that enables targeted degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner.

EpiBiologics正在推进针对膜和细胞外蛋白质的下一代蛋白质降解管道和平台。EpiBiologics是在加州大学旧金山分校（UCSF）科学创始人吉姆·威尔斯博士的开创性工作基础上成立的。该公司专有的EpiTAC平台是一种模块化双特异性抗体系统，能够以组织特异性方式靶向降解疾病驱动膜和细胞外蛋白。

Preclinical anti-tumor data support the innovative EpiTAC approach to extracellular protein degradation as the company moves toward the clinic. Headquartered in the San Francisco Bay Area, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas, including oncology, immunology, neurodegeneration and metabolism.

随着公司走向临床，临床前抗肿瘤数据支持创新的EpiTAC细胞外蛋白降解方法。EpiBiologics总部位于旧金山湾区，由领先的医疗保健投资者支持，旨在开发跨多个治疗领域的一流和一流的靶向治疗，包括肿瘤学，免疫学，神经退行性疾病和代谢。

For more information, please visit epibiologics.com and follow us on LinkedIn..

有关更多信息，请访问epibiologics.com并在LinkedIn上关注我们。。